Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
1.32
USD
|
-1.49%
|
|
-10.20%
|
+30.69%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,164
|
343.6
|
75.28
|
55.37
|
81.33
|
-
|
-
|
Enterprise Value (EV)
1 |
1,029
|
214.6
|
-114.3
|
-58.93
|
21.63
|
81.33
|
81.33
|
P/E ratio
|
-8.79
x
|
-1.82
x
|
-0.55
x
|
-0.54
x
|
-1.23
x
|
-1.97
x
|
-2.15
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
203
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
203
x
|
EV / EBITDA
|
-9.18
x
|
-1.17
x
|
0.85
x
|
0.59
x
|
-0.31
x
|
-1.11
x
|
-1.08
x
|
EV / FCF
|
-12,604,019
x
|
-1,485,001
x
|
948,894
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
3.83
x
|
1.08
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,535
|
54,107
|
54,553
|
54,820
|
61,612
|
-
|
-
|
Reference price
2 |
25.57
|
6.350
|
1.380
|
1.010
|
1.320
|
1.320
|
1.320
|
Announcement Date
|
3/3/21
|
3/3/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.4
|
EBITDA
1 |
-
|
-112.1
|
-184.2
|
-134.7
|
-99.28
|
-69.97
|
-73.4
|
-75.06
|
EBIT
1 |
-37.19
|
-112.9
|
-185.7
|
-138.4
|
-103
|
-73.54
|
-85.07
|
-88.86
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-22,215.25%
|
Earnings before Tax (EBT)
1 |
-
|
-112.2
|
-185.4
|
-136.1
|
-102.1
|
-69.3
|
-82.67
|
-86.69
|
Net income
1 |
-
|
-112.2
|
-185.4
|
-136.1
|
-102.1
|
-69.3
|
-82.67
|
-86.69
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-21,673.58%
|
EPS
2 |
-2.430
|
-2.910
|
-3.480
|
-2.500
|
-1.860
|
-1.075
|
-0.6700
|
-0.6133
|
Free Cash Flow
|
-
|
-81.67
|
-144.5
|
-120.5
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/3/20
|
3/3/21
|
3/3/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-50.49
|
-41.93
|
-38.89
|
-26.6
|
-27.3
|
-34.9
|
-24.41
|
-22.32
|
-17.64
|
-
|
-17.34
|
-17.58
|
-17.82
|
-
|
-
|
EBIT
1 |
-51.16
|
-42.81
|
-39.81
|
-27.53
|
-28.24
|
-35.88
|
-25.39
|
-23.28
|
-18.45
|
-18.05
|
-18.27
|
-18.5
|
-18.72
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-51.15
|
-42.81
|
-39.54
|
-26.7
|
-27.07
|
-34.34
|
-23.86
|
-27.11
|
-16.76
|
-16.71
|
-17.17
|
-17.5
|
-17.92
|
-
|
-
|
Net income
1 |
-51.15
|
-42.81
|
-39.54
|
-26.7
|
-27.07
|
-34.34
|
-23.86
|
-27.11
|
-16.76
|
-16.71
|
-17.17
|
-17.5
|
-17.92
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9500
|
-0.7900
|
-0.7300
|
-0.4900
|
-0.4900
|
-0.6300
|
-0.4400
|
-0.4900
|
-0.3000
|
-0.3000
|
-0.3000
|
-0.2500
|
-0.2550
|
-0.2000
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/16/22
|
8/4/22
|
11/10/22
|
3/6/23
|
5/11/23
|
8/7/23
|
11/13/23
|
3/4/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
135
|
129
|
190
|
114
|
59.7
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-81.7
|
-145
|
-120
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-90.3%
|
-59.5%
|
-52.4%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-44.3%
|
-54.3%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
253.3
|
341.5
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.680
|
5.870
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-2.170
|
-
|
-
|
-
|
-
|
Capex
1 |
1.15
|
17.6
|
2.27
|
0.15
|
4
|
4.4
|
4.8
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
1,200%
|
Announcement Date
|
3/3/21
|
3/3/22
|
3/6/23
|
3/4/24
|
-
|
-
|
-
|
Last Close Price
1.32
USD Average target price
6.75
USD Spread / Average Target +411.36% Consensus |
1st Jan change
|
Capi.
|
---|
| +30.69% | 81.33M | | +9.42% | 115B | | +11.84% | 106B | | -1.05% | 21.96B | | -14.15% | 21.87B | | -5.29% | 19.21B | | -4.16% | 18.08B | | -38.29% | 17.71B | | +7.99% | 14.32B | | +36.24% | 12.42B |
Bio Therapeutic Drugs
|